SCHEMBL22714741

SCHEMBL22714741

CC(C)(C)OC(=O)N1CCC(O)CC12CCC2

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 1/20 0.42
CHRM1 P11229 1/20 0.42
CHRM3 P20309 1/20 0.42
HPGD P15428 1/20 0.38
EPHX1 P07099 1/20 0.37
GRIN2B Q13224 1/20 0.36
GRIN2C Q14957 1/20 0.36
JAK3 P52333 2/20 0.36
PREP P48147 2/20 0.35
HSD11B1 P28845 1/20 0.35
EPHX2 P34913 1/20 0.35
USP2 O75604 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
CTSK P43235 1/20 0.34
RECQL P46063 1/20 0.34
HSD17B10 Q99714 1/20 0.34
KDM1A O60341 1/20 0.34
MEN1 O00255 1/20 0.33
ALDH1A1 P00352 1/20 0.33
MAPT P10636 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21752540 0.94 CHRM2 (0.44) CHRM2CHRM1CHRM3HPGDEPHX1
SCHEMBL21274184 0.85 GRIN2B (0.43) CHRM2CHRM1CHRM3HPGDEPHX1
SCHEMBL26916063 0.85 CHRM2 (0.44) CHRM2CHRM1CHRM3HPGDEPHX1
SCHEMBL4480866 0.84 PREP (0.40) CHRM2CHRM1CHRM3HPGDEPHX1
SCHEMBL29243416 0.83 HSD17B10 (0.46) CHRM2CHRM1CHRM3HPGDEPHX1
SCHEMBL31078757 0.82 CHRM2 (0.44) CHRM2CHRM1CHRM3HPGDEPHX1
SCHEMBL15716251 0.81 CHRM2 (0.42) CHRM2CHRM1CHRM3HPGDEPHX1
SCHEMBL5140938 0.80 CHRM2 (0.45) CHRM2CHRM1CHRM3HPGDEPHX1
SCHEMBL4488388 0.80 JAK3 (0.41) CHRM2CHRM1CHRM3HPGDEPHX1
SCHEMBL27374605 0.79 JAK3 (0.43) CHRM2CHRM1CHRM3HPGDEPHX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4665733-A1 AMINO-SUBSTITUTED PYRROLOTRIAZINE DERIVATIVES AS INHIBITORS OF SGK1 Bristol-Myers Squibb Company (US) 2025-12-24 EP disclosed
US-12466820-B2 Amino quinazoline derivatives as P2X3 inhibitors CHIESI FARMACEUTICI S.P.A. (IT) 2025-11-11 US disclosed
US-20250332173-A1 COMPOUNDS AND METHODS FOR MODULATING NUCLEIC ACID SPLICING REMIX THERAPEUTICS INC (US) 2025-10-30 US disclosed
WO-2024173323-A1 AMINO-SUBSTITUTED PYRROLOTRIAZINE DERIVATIVES AS INHIBITORS OF SGK1 BRISTOL-MYERS SQUIBB COMPANY (US) 2024-08-22 WO disclosed
EP-4416141-A1 COMPOUNDS AND METHODS FOR MODULATING NUCLEIC ACID SPLICING Remix Therapeutics Inc. (US) 2024-08-21 EP disclosed
US-20240174662-A1 SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES CILAG AG (CH) 2024-05-30 US disclosed
CN-113891745-B As P2X3Aminoquinazoline derivatives of inhibitors 奇斯药制品公司 2024-05-07 CN disclosed
EP-4284802-A1 SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES Janssen Biotech, Inc. (US) 2023-12-06 EP disclosed
WO-2023064880-A1 COMPOUNDS AND METHODS FOR MODULATING NUCLEIC ACID SPLICING REMIX THERAPEUTICS INC. (US) 2023-04-20 WO disclosed
WO-2023064880-A1 COMPOUNDS AND METHODS FOR MODULATING NUCLEIC ACID SPLICING REMIX THERAPEUTICS INC. (US) 2023-04-20 WO disclosed
WO-2022165530-A1 SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES JANSSEN BIOTECH, INC. (US) 2022-08-04 WO disclosed
US-20220227749-A1 AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS CHARLES RIVER LABORATORIES, INC. 2022-07-21 US disclosed
EP-3976180-A1 AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS Chiesi Farmaceutici S.p.A. (IT) 2022-04-06 EP disclosed
WO-2020239952-A1 AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2020-12-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250332173-A1 COMPOUNDS AND METHODS FOR MODULATING NUCLEIC ACID SPLICING SNRPA, NSUN2, SNRPA1 CHRM2 4881/4885CHRM1 4848/4885CHRM3 4757/4885
US-20220227749-A1 AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS P2RX3, P2RX5, P2RX1 CHRM2 276/4885CHRM1 223/4885CHRM3 40/4885
US-12466820-B2 Amino quinazoline derivatives as P2X3 inhibitors P2RX3, P2RX5, P2RX1 CHRM2 276/4885CHRM1 223/4885CHRM3 40/4885
US-20240174662-A1 SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES SIK2, SIK1, SGK2 CHRM2 4838/4885CHRM1 4859/4885CHRM3 4785/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.